Table 1

Molecular Antimicrobial Resistance Surveillance for Neisseria gonorrhoeae, Northern Territory, Australia

David Whiley

, Ella Trembizki, Cameron Buckley, Kevin Freeman, Robert W. Baird, Miles Beaman, Marcus Y. Chen, Basil Donovan, Ratan L. Kundu, Christopher K. Fairley, Rebecca Guy, Tiffany Hogan, John M. Kaldor, Mahdad Karimi, Athena Limnios, David G. Regan, Nathan Ryder, Jiunn-Yih Su, James Ward, and Monica M. Lahra

Author affiliations: Pathology Queensland Central Laboratory, Brisbane, Queensland, Australia (D. Whiley); The University of Queensland, Brisbane (D. Whiley, E. Trembizki, C. Buckley); Royal Darwin Hospital, Darwin, Northern Territory, Australia (K. Freeman, R.W. Baird); University of Western Australia, Nedlands, Western Australia, Australia (M. Beaman); University of Notre Dame Australia, Fremantle, Western Australia, Australia (M. Beaman); Western Diagnostic Pathology, Perth, Western Australia, Australia (M. Beaman, M. Karimi); Alfred Health, Carlton, Victoria, Australia (M. Chen, C.K. Fairley); Central Clinical School, Monash University, Melbourne, Victoria, Australia (M. Chen, C.K. Fairley); Sydney Hospital, Sydney, New South Wales, Australia (B. Donovan); University of New South Wales, Sydney (B. Donovan, R. Guy, J.M. Kaldor, D.G. Regan, N. Ryder, M.M. Lahra); Prince of Wales Hospital, Sydney (R.L. Kundu, T. Hogan, A. Limnios, M.M. Lahra); School of Medical Sciences, Hunter New England Local Health District, Sydney (N. Ryder); Menzies School of Health Research and Charles Darwin University, Darwin (J.-Y. Su); South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia (J. Ward); Flinders University, Adelaide (J. Ward)

Main Article

PCR results for the 1,629 NAAT-positive Neisseria gonorrhoeae clinical samples taken from patients in the Northern Territory of Australia, 2014*

Assay and targets	Results
	CAZ region, n = 441		ZAP region, n = 1,188		Total for both regions, n = 1,629
	No. samples/no. tested	% Samples (95% CI)	No. samples/no. tested	% Samples (95% CI)	No. samples/no. tested	% Samples (95% CI)
GyrA91-PCR (gyrA)
Wild type (S91)	235/297	79.1 (74.1–83.4)	922/931	99.0 (98.2–99.5)	1,157/1,228	94.2 (92.8–95.4)
S91F	62/297	20.9 (16.6–25.9)	9/931	1.0 (0.5–1.8)	71/1,228	5.8 (4.6–7.2)
Uncharacterized†	144	32.6	257	21.6	401/1,629	24.6
PPNG-PCR
Negative	252/286	88.1 (83.8–91.4)	879/888	99 (98.1–99.5)	1,131/1,174	96.3 (95.1–97.3)
PPNG	34/286	11.9 (8.6–16.2)	9/888	1 (0.5–1.9)	43/1,174	3.7 (2.7–4.9)
Uncharacterized†	155	35.1	300	25.3	455/1,629	27.9
2611-PCR (23S rRNA)
Wild type	321/321	100 (98.8–100)	958/960	99.8 (99.2–99.9)	1,279/1,281	99.8 (99.4–100)
C2611T	0/321	0 (0–1.2)	2/960	0.2 (0.1–0.8)	2/1,281	0.2 (0–0.6)
Uncharacterized†	120	27.2	228	19.2	348/1,629	21.4
2059-PCR (23S rRNA)
Wild type	319/319	100 (98.8–100)	1,004/1,004	100 (99.6–100)	1,323/1,323	100 (99.7–100)
A2059G	0/319	0 (0–1.2)	0/1,004	0 (0–0.4)	0/1,323	0 (0–0.3)
Uncharacterized†	122	27.7	184	15.5	306/1,629	18.8
PorB-PCR (porB)
G101/A102	98/286	34.3 (29–39.9)	125/835	15.0 (12.7–17.6)	223/1,121	19.9 (17.7–22.3)
[G101/A102, non-PPNG]‡	[80/280]	[28.6 (23.4–34.1)]	[116/823]	[14.1 (11.9–16.6)]	[196/1,103]	[17.8 (15.6–20.1)]
PorB1a	152/286	53.1 (47.4–58.9)	699/835	83.7 (81.1–86.1)	851/1,121	75.9 (73.3–78.3)
[PorB1a, non-PPNG]‡	[120/267]	[44.9 (39.1–50.9)]	[627/770]	[81.3 (78.4–83.9)]	[747/1,037]	[72.0 (69.2–74.7)]
Mutant§	32/286	11.2 (8–15.4)	3/835	0.4 (0.1–1.1)	35/1,121	3.1 (2.3–4.3)
PorB1a and G101/A102	4/286	1.4 (0.5–3.5)	6/835	0.7 (0.3–1.6)	10/1,121	0.9 (0.5–1.6)
PorB1a and mutant§	0/286	0 (0–1.3)	2/835	0.2 (0.1–0.9)	2/1,121	0.2 (0–0.6)
Uncharacterized†	155	35.1	353	29.8	508/1,629	31.2
A-deletion-PCR (MtrR)
Wild type	280/318	88.1 (84–91.2)	944/950	99.4 (98.6–99.7)	1,224/1,268	96.5 (95.4–97.4)
[Wild type, non-PPNG]‡	[226/284]	[79.6 (74.5–84.1)]	[861/873]	[98.6 (97.6–99.2)]	[1,087/1,157]	[93.9 (92.4–95.2)]
A-deletion	38/318	11.9 (8.8–16)	6/950	0.6 (0.3–1.4)	44/1268	3.5 (2.6–4.6)
Uncharacterized†	123	27.9	238	20	361/1629	22.2
mosaicPBP2-PCR (penA)
Negative	431/441	97.7 (95.9–98.8)	1,188/1,188	100 (99.7–100)	1,619/1,629	99.4 (98.9–99.7)
Positive	10/441	2.3 (1.2–4.1)	0/1188	0 (0–0.3)	10/1,629	0.6 (0.3–1.1)
Uncharacterized†¶	NA	NA	NA	NA	NA	NA
A8806-PCR (penA)
Negative	441/441	100 (99.1–100)	1,188/1,188	100 (99.7–100)	1,629/1,629	100 (99.8–100)
Positive	0/441	0 (0–0.9)	0/1,188	0 (0–0.3)	0/1,629	0 (0–0.2)
Uncharacterized†¶	NA	NA	NA	NA	NA	NA

*NA, not applicable; NAAT, nucleic acid amplification test; PPNG, penicillinase-producing N. gonorrhoeae.
†These samples could not be characterized by the respective PCR assay.
‡These PorB-PCR and A-deletion-PCR results were combined with the PPNG-PCR results to exclude those that were PPNG. Uncharacterized PPNG-PCR results were omitted from total numbers.
§Mutant = G101K/A102D, G101K/A102N or G101K/A102G.
¶All negative results for the mosaicPBP2-PCR and A8806-PCR were considered valid (i.e., characterized) given that pooled samples were used for screening, and it was therefore not possible to ascertain characterization for individual samples.

Main Article

Page created: August 14, 2017

Page updated: August 14, 2017

Page reviewed: August 14, 2017

The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.